Pimitespib clinical trials
Also written TAS-116.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses pimitespib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Taiho Pharmaceutical Co., Ltd. (1) · Taiho Oncology, Inc. (1) · Brown University (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test pimitespib.
- Dec 2026A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Phase 1 · Taiho Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses pimitespib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Active, not recruitingPhase 1Taiho Pharmaceutical Co., Ltd.NCT05245968Written as Pimitespib
- TAS-116 Plus Palbociclib in Breast and Rb-null CancerWithdrawnPhase 1Brown UniversityNCT05655598Written as TAS-116
- A Study of TAS-116 in Patients With Solid TumorsCompletedPhase 1Taiho Oncology, Inc.NCT02965885Written as TAS-116
Given beside what is tested · 1 — pimitespib is usual care or a partner of the new treatment
Codes
What other systems call pimitespib · ClinicalTrials.gg INT000199
- MeSH (NLM) C000596495pimitespibOne source ClinicalTrials.gov
- UNII (FDA) PLO044MUDZPIMITESPIBConfirmed FDA, Wikidata
- Wikidata Q114043898pimitespibConfirmed FDA, Wikidata
- NCI Thesaurus C134448PimitespibOne source FDA
- DrugBank DB14876One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000596495 | pimitespib | One source ClinicalTrials.gov |
| UNII (FDA) | PLO044MUDZ | PIMITESPIB | Confirmed FDA, Wikidata |
| Wikidata | Q114043898 | pimitespib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C134448 | Pimitespib | One source FDA |
| DrugBank | DB14876 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.